Dexcom Inc
NASDAQ:DXCM
Intrinsic Value
DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. [ Read More ]
The intrinsic value of one DXCM stock under the Base Case scenario is 45.19 USD. Compared to the current market price of 136.35 USD, Dexcom Inc is Overvalued by 67%.
Valuation Backtest
Dexcom Inc
Run backtest to discover the historical profit from buying and selling DXCM stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Dexcom Inc
Current Assets | 4.4B |
Cash & Short-Term Investments | 2.7B |
Receivables | 987.5m |
Other Current Assets | 714.3m |
Non-Current Assets | 1.8B |
PP&E | 1.2B |
Intangibles | 159.7m |
Other Non-Current Assets | 494.4m |
Current Liabilities | 1.6B |
Accounts Payable | 276.4m |
Accrued Liabilities | 1.3B |
Other Current Liabilities | 25.9m |
Non-Current Liabilities | 2.6B |
Long-Term Debt | 2.5B |
Other Non-Current Liabilities | 147.1m |
Earnings Waterfall
Dexcom Inc
Revenue
|
3.6B
USD
|
Cost of Revenue
|
-1.3B
USD
|
Gross Profit
|
2.3B
USD
|
Operating Expenses
|
-1.7B
USD
|
Operating Income
|
614.3m
USD
|
Other Expenses
|
-72.8m
USD
|
Net Income
|
541.5m
USD
|
Free Cash Flow Analysis
Dexcom Inc
DXCM Profitability Score
Profitability Due Diligence
Dexcom Inc's profitability score is 63/100. The higher the profitability score, the more profitable the company is.
Score
Dexcom Inc's profitability score is 63/100. The higher the profitability score, the more profitable the company is.
DXCM Solvency Score
Solvency Due Diligence
Dexcom Inc's solvency score is 78/100. The higher the solvency score, the more solvent the company is.
Score
Dexcom Inc's solvency score is 78/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DXCM Price Targets Summary
Dexcom Inc
According to Wall Street analysts, the average 1-year price target for DXCM is 154.35 USD with a low forecast of 123.22 USD and a high forecast of 178.5 USD.
Ownership
DXCM Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
DXCM Price
Dexcom Inc
Average Annual Return | 45.62% |
Standard Deviation of Annual Returns | 41.71% |
Max Drawdown | -58% |
Market Capitalization | 52.5B USD |
Shares Outstanding | 385 520 000 |
Percentage of Shares Shorted | 4.28% |
DXCM News
Last Important Events
Dexcom Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Dexcom Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. The company is headquartered in San Diego, California and currently employs 6,300 full-time employees. The company went IPO on 2005-04-14. The firm is primarily focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for use by people with diabetes and by healthcare providers. Its products include Dexcom G6 and Dexcom Share. The G6 is a CGM system that can be used as part of an integrated system with other compatible medical devices and electronic interfaces, which may include automated insulin dosing systems, insulin pumps, blood glucose meters or other electronic devices used for diabetes management. Its Dexcom Share remote monitoring system, offered for use with its Dexcom system, uses an app on the patient’s iPhone, iPod touch, iPad or Android mobile device to securely and wirelessly transmit glucose information to the cloud and then to apps on the mobile devices of up to five designated recipients, who can remotely monitor a patient’s glucose information and receive alert notifications.
Contact
IPO
Employees
Officers
The intrinsic value of one DXCM stock under the Base Case scenario is 45.19 USD.
Compared to the current market price of 136.35 USD, Dexcom Inc is Overvalued by 67%.